Service sheet

Humanized models for oncology research

Unlocking the full potential of cancer immunotherapy through humanized *in vivo* platforms

Humanized mouse models (HIS mice) are advanced *in vivo* platforms reconstituted with human immune components to closely mimic human tumor-immune interactions. These models are vital for evaluating the efficacy and mechanism of action of cancer immunotherapies.

Preclinical packages

When selecting or designing a HIS model, consider these essential parameters:

- **Mechanism of action** (MoA) of your active entity
- **Mouse strain** compatibility (e.g. NSG, NOG-EXL)
- **Type of immune cells** supported (e.g. T cell subsets, DCs, NK cells)
- **Tumor type** (solid or hematologic, cell line or PDX)
- **Readout endpoints** (TILs, biomarker release, survival)



Above: Monitoring of tumor volume. A bispecific antibody cured human breast BT-474 tumor in PBMC-reconstituted mice.

Why use humanized models?

- **Reflects human biology:** HIS models recreate the complexity of human tumor-immune interactions, improving translational relevance.
- **De-risks development:** Detect immune-related effects and therapeutic activity early in development.
- **Tailors to your drug's mechanism of action**
- **Enhances patient targeting:** Study immune infiltration and biomarkers to refine clinical strategies and responder profiles.
- **Supports regulatory readiness:** Generate robust, immune-relevant data to strengthen IND submissions and regulatory confidence.

With over 30 years of translational experience, Oncodesign Services offers comprehensive preclinical solutions, a strategic pathway to accelerate your immuno-oncology program.

Next steps

Reach out to your relationship manager or contact us at:

- oncodesign-services.com
- contact@oncodesign-services.com

More information

Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services. Our mission is to help researchers discover innovative therapies against cancers and serious diseases with high medical need. We have been performing translational science for over 30 years, providing the partnership required to help our clients progress from therapeutic target to advanceable preclinical candidates.

oncodesign services

DO NOT PRINT UNLESS NECESSARY

oncodesign-services.com
contact@oncodesign-services.com